Vaccine Design and Testing – News and Features

Researchers have figured out a way to genetically disarm the virus and making the agent safe to study under conditions far less stringent than those currently imposed.

The Company has been developing the CELLECTRA™ electroporator as its lead clinical medical device for delivering DNA vaccine and therapy products.

AbD Serotec has announced the publication of a scientific research paper in Journal of Virology from one of its customers.

CLC bio will upgrade and expand ACE’s bioinformatics platform to the most up-to-date and relevant software, including protein vaccine target characterization.

The acquisition will bring together IVT's signature VacciMax® platform with Immunotope's portfolio of immunotherapeutic antigens and antigen discovery platform.

The work validates the suitability of the platform for commercial applications in therapeutic cancer and infectious disease indications.

The technology will help Novartis to support the development and construction of new vaccine strains to produce influenza vaccines.

The agreements to enhance the potency of DNA-based vaccines against infectious diseases and cancers will utilize Inovio’s DNA delivery technology.

Researchers have identified three gene variants in the DNA of 486 HIV infected people that appear to have helped some of the patients fight off the virus and delay the onset of full-blown AIDS.

The award supports advanced preclinical studies and manufacturing process development for new adjuvant technologies based on Alphavax’s vector platform.